2015 BPD Header
Archived Content

Cell Culture & Cell Line Development

Speaker Bios
Optimizing Cell Culture Technology
August 18-19, 2014


Woo Suk Ahn, Ph.D., Research Associate, Bioinformatics and Metabolic Engineering, Massachusetts Institute of Technology (MIT) 
Woo Suk Ahn is a Post Doc in Chemical Engineering at MIT. Ahn worked at LG Life Sciences in R&D Biotech Group (2000– 2008), where he developed recombinant strains and culture processes for the production of biogeneric drugs, including human growth hormone with Saccharomyces cerevisiae and erythropoietin with CHO cells. Ahn earned his Ph.D. degree in Chemical Engineering at University of Delaware (2008 – 2012). His doctoral research focused on developing improved methods for measuring metabolic fluxes in mammalian cells using isotopic-tracers and mass spectrometry. Now, he is studying on tumor metabolism and oleaginous yeast metabolism for biofuel production in Gregory Stephanopoulos group at MIT (2012 - present). 

James Brady, Ph.D., Director, Technical Applications, MaxCyte, Inc.

Dr. Brady received a B.S. in Biology from the College of William and Mary and a Ph.D. in Genetics from Indiana University. Following a postdoctoral fellowship in the National Eye Institute of the National Institutes of Health, Dr. Brady worked for four years at MetaMorphix, Inc. as a Senior Scientist and as a Group Leader in the Company’s Transgenic Livestock program, where he managed internal and external projects focused on improving livestock by modifying the activity of growth and differentiation factors. Later, Dr, Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Since 2004, has been with MaxCyte, Inc., where he serves as Director of Technical Applications.

Jeffrey Chalmers, Ph.D., Professor, Chemical and Biomolecular Engineering, Director, Analytical Cytometry Shared Resource, Comprehensive Cancer Center, The Ohio State University

Jeffrey J. Chalmers is a Professor in the Department of Chemical and Biomolecular and Director of the Analytical Cytometery Shared Resource at the Ohio State University. He has received a National Science Foundation Young Investigator Award, was elected a Fellow of American Institute for Medical and Biological Engineering in 2001, and in 2005 was elected a fellow of the AAAS. He has published over 130 peer reviewed articles, book chapters, a book in bioengineering, and nine issued patents; a majority of which involve magnetism and magnetic cell separation. Professor Chalmers received his Ph.D. from Cornell University in 1988 and his B.S. in Chemical Engineering from U.C. Berkeley and a B.A. from Westmont College in 1983.

Véronique Chotteau, Ph.D., Researcher, CETEG Cell Technology Group, Industrial Biotechnology, KTH Royal Institute of Technology

Dr. Véronique Chotteau (M.Sc.Elec.Eng. Univ. Libre Bruxelles, M.Sc. Biotechnol. Univ. Libre Bruxelles, Ph.D Louvain Univ., Belgium) has more than 25 years of experience in mammalian cell culture cultivation and more than 10 years of experience in biopharmaceutical industry at Pharmacia-Upjohn and Biovitrum, including different responsibilities as expert in animal cell culture development (perfusion, fed-batch, small-scale, pilot-scale and commercial size/GMP), pilot plant head, senior project manager, business development support. Véronique was offered to take over the group of Cell Technology, Industrial Biotechnology/Bioprocess Design, Fac. of Biotechnology, KTH-Royal Institute of Technology, Stockholm, Sweden, in 2008. The activities of her group are focused on established cell-based processes (perfusion, metabolic flux analysis modeling) with focus on industrial systems and stem cell bioprocessing aiming at developing large-scale processes.

Michael R. Dyson, Ph.D., Senior Research Associate, Biochemistry, University of Cambridge, and Group Leader, IONTAS, Ltd.

Mike has over 20 years experience in protein and small molecule chemistry, molecular biology and assay development gained during post-doctoral research at the Massachusetts Institute of Technology, Universities of Edinburgh and Cambridge and the biotechnology industry. He has published 27 papers (cited over 800 times, h-index 16), 3 book chapters, edited a book on protein expression and is inventor on 4 US patent and patent applications. He was previously Head of Protein Engineering at Acambis plc, Group Leader at Sense Proteomic Ltd and was the Project Leader, responsible for protein expression, within the Atlas Project at the Wellcome Trust Sanger Institute.

Bert Frohlich, Ph.D., Director, Bioengineering, Shire Human Genetic Therapies

Dr. Frohlich is a Biochemical Engineer with 20+ years of experience in the biotechnology, pharmaceutical, and chemical industries, providing leadership in management of people and in the development of useful biotechnologies. Dr. Frohlich directs a team of engineers and scientists in development and tech transfer of biological processes and primary recovery operations for manufacture of protein therapeutics. The Bioengineering group conducts small-scale cell culture and bench-scale bioreactor process development and participates in project management, tech transfer and new technology development. Dr. Frohlich received his B.S. and M.Eng. degrees in Chemical Engineering from Cornell University, and his Ph.D. in Biochemical Engineering from Tufts University.

Sofie Goetschalckx, Head, Cell Culture Manufacturing Science Team, MSAT, Cell Culture and Microbiology, Genzyme, A Sanofi Company

Sofie Goetschalckx, M.S. has graduated Biochemistry Sciences at University of Antwerp, Belgium in 2000. Her professional carrier started at Pharming N.V. where she was a member of R&D organization. Shortly after Genzyme’s acquisition; Sofie became responsible for start-up of cell culture team and to establish the new laboratories. She played pivotal role in the technical transfer, scale up and validation of the cell culture processes for perfusion and fed-batch process. Today, she is head of Upstream Manufacturing Science team that is responsible for development of qualified small scale models for various large scale cell culture processes and as well as providing Global support to all Genzyme’s Manufacturing Sites. The most important part of her work is exploring innovative tools and processes and impact evaluation towards at scale manufacturing processes.

Martin Jordan, Ph.D., Scientist, Biotech Process Sciences, Merck Serono SA 

During more than 20 years of activity in upstream processes Martin Jordan accumulated a solid expertise in different topics of mammalian cell culture. This includes his thesis about the shear stress sensitivity of cells, the optimization of large-scale transient expression at Genentech (1993-1995) and many additional studies and publications during 9 years within the laboratory of professor Florian Wurm at the EPFL in Switzerland. New disposable products that successfully entered the market as “tubespin”, “Mini PCV” or Volupac™ were also invented during this period.
In 2005 Martin Jordan joined the MerckSerono manufacturing site in Vevey as head of the media development group. As a scientist he continuously improves cell culture media and fed-batch processes.

Lada Laenen, Ph.D., Head, Cell Culture and Microbiology, MSAT, Genzyme, A Sanofi company

Dr. Lada Laenen has graduated Biotechnology Sciences at University of Zagreb, Croatia in 1998 and obtained her doctoral degree in Natural Sciences in 2001 at University of Kaiserslautern, Germany. Lada has more than 15 years’ experience in the biopharmaceutical industry. Her professional career started at PLIVA Inc. Zagreb Croatia, continuing at MIXIS Genetics; Paris, France, in different development roles focusing her work on antibiotic production. After her move to Belgium, she established research department at Flen Pharma NV with focus on tissue cultures and clinical studies in collaboration with different Belgium hospitals and then moved to Johnson & Johnson for its Tibotec/Virco branch where she worked in the HIV field. In 2007, she joined Genzyme, and following Sanofi acquisition in 2011, she is heading Cell Culture and Microbiology departments, focusing on innovation, process development and validation, regulatory submissions and providing support towards commercial manufacturing.

Hanuman Mallubhotla, Ph.D., Research Director and Head, Biopharmaceutical Development, Syngene International, Ltd.

Hanuman Mallubhotla has a(n) M. Ch.E. from Villanova Univeristy and a Ph. D. from Rensselaer, both in USA. He won the graduate student award of the North American Membrane Society in 1994 and the Carl T. Humphrey Alumni Award from Villanova in 2006. He contributed toward making Bristol-Myers Squibb’s first biologic, the world’s first biosimilar antibody and India’s first EMA-approved biologic. Currently, he looks after the development of biologics at a contract research and manufacturing organization.

Alan G. Ryder, Ph.D., Senior Lecturer, Nanoscale Biophotonics Laboratory, School of Chemistry, National University of Ireland-Galway

Dr. Alan G. Ryder is a Senior lecturer in the School of Chemistry at the National University of Ireland, Galway (NUIG). He has a B.Sc. and Ph.D. in chemistry from NUIG. After a stint as a postdoctoral researcher in UCC, he rejoined NUIG in 1997 to work on developing quantitative Raman spectroscopy based methods for measuring illicit narcotics. In 2003 he formed the Nanoscale Biophotonics Laboratory (NBL) which is focussed on the use of photonics and chemometrics technologies for life and physical science applications. In 2006 obtained tenure in the School of Chemistry at NUIG where he lectures mainly in spectroscopy and has two core research areas: Analytical Sciences and Photonics which cover a wide range of applications. In the Analytical Sciences domain the main research area is the development of rapid, quantitative analytical methods for the analysis of complex materials with particular focus on biopharmaceutical manufacturing. Key methods employed include Raman and Fluorescence spectroscopies and chemometrics. He has collaborated with a range of industry partners including Bristol-Myers Squibb, Janssen-Biologics, Merck, Agilent, and Kaiser Optical Systems. He has authored in excess of 70 publications, generated 3 patents, graduated 11 PhD students.

Yung-shyeng Tsao, Ph.D., Senior Principal Scientist, BioProcess Technology and Expression, Biologics Bioprocess Development, Merck & Co.

Dr. Tsao received his Ph.D. (biochemistry/ biophysics) from the University of Tennessee, Knoxville, specialized in liposome and membrane technologies. He was a postdoctoral fellow (molecular/ cell biology) in New York University, specialized in membrane trafficking and protein secretion mechanisms. He joined Schering-Plough Research Institute in 1988 and developed cell lines for gene therapy and recombinant protein production. He joined Merck in 2009. He has published in the area of protein isolation and characterization, membrane biophysics and fusion mechanisms, liposome drug targeting, membrane trafficking, protein secretion and degradation mechanisms, animal cell culture media, serum-free virus production, aggregated cell monitoring, cell growth-protein productivity-metabolic modeling, cell culture miniaturization and automation, transcriptome and integrative pathway analysis. He has also presented and served as panelist in international conferences.

Len van Zyl, Ph.D., CEO and CSO, ArrayXpress Inc.

Dr. Len van Zyl is the CEO and CSO of ArrayXpress Inc. ArrayXpress is a Next Generation Genomics services company founded with the vision of providing a complete solution for anyone needing to implement genomics technologies in their research agenda. Dr. van Zyl received a Top 50 Entrepreneurs award for 2010. This award honors entrepreneurs who have made a significant impact on the scientific and business community. He remains an adjunct research professor at NC State University. Dr. van Zyl received his Ph.D. in Microbiology and Genetics from the University of the Free State in the Republic of South Africa.

Jörg von Hagen, Ph.D., Director, Global Cell Culture R & D, Merck

Dr. Jörg von Hagen is director of the global Merck Millipore Cell Culture Media Research and Development group. Having studied biotechnology and signal transduction in Giessen and Darmstadt, he received his academic degree with an award-winning thesis in 2001. Dr. von Hagen has more than 10 years of practical expertise in Pharma R&D as scientist in the therapeutic areas cardio vascular and oncology research. After the PDH thesis von Hagen was heading a laboratory for sample preparation in proteomics. Since 2010 von Hagen is responsible for the cell culture media physico chemical research for dry powder cell culture media. He is active member of the European Society of Animal Cell Technology (ESACT) and the Animal Cell Technology Industrial Platform (ACTIP).

Hua Zhong, M.D., Ph.D., FCAP, Assistant Professor, Pathology and Lab Medicine, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School

Dr. Zhong’s medical education and initial clinical/research training was in China. He then became a research fellow at Johns Hopkins Oncology Center, and research faculty at Emory University School of Medicine. After conducting 10-year basic and translational research in the field of tissue hypoxia, Dr. Zhong is now employed at Rutgers CINJ/Rutgers RWJMS as a surgical pathologist, certified in Anatomic Pathology and Clinical Pathology.

Matthew Zustiak, Ph.D., Principal Scientist, Cell Culture Development, Gallus Biopharmaceuticals

After completing his Bachelors in Chemical Engineering at the University of Michigan, Matt began his carrier working at the National Cancer Institute (NCI). As a Development engineer in the Biopharmaceutical Development Program, he worked with both prokaryotic and eukaryotic expression systems for the production of toxins, fusion proteins, mAbs and viruses. After getting a taste of what the field of biotechnology had to offer, Matt returned to graduate school to study Chemical and Biomolecular Engineering at Johns Hopkins University. Through a collaboration between Johns Hopkins and the NCI, Matt was able to perform the research for his dissertation under the direction of Prof. Michael Betenbaugh in the labs of the NCI where he focused on engineering mammalian expression systems (primarily CHO) for enhanced biotherapeutic protein expression. This was primarily accomplished through anti-apoptosis and cell cycle engineering strategies. After completing his graduate work, Matt Joined MedImmune as a scientist in the Process Cell Culture group developing new processes for transient gene expression in CHO cells. Matt is currently a Principal Scientist at Gallus BioPharmaceuticals where he is responsible for process development for fed-batch and perfusion processes for mammalian cells.

Speaker Bios
Bioproduction: Scale, Bioreactors & Disposables
August 20-21, 2014

William Brazier, Principal Engineer, Amgen

Henry Bungay, Ph.D., Emeritus Professor, H.P. Isermann Department of Chemical Engineering, Rensselaer Polytechnic Institute

Henry Bungay, Emeritus Professor of Chemical Engineering, has rare back and forth from industry (Eli Lilly) to academia (Virginia Polytechnic Institute and Clemson University), to industry (V.P. at Worthington Biochemical Corporation), and again to academia (Rensselaer Polytechnic Institute) with stints at the National Science Foundation and the US Energy Research and Development Administration.

Cheng Cheng, Process Engineer, Late Stage Cell Culture Development, Genzyme, A Sanofi company

Cheng Cheng, graduated from East China University of Science and Technology with a bachelor degree in Bioengineering; earned Master in Science of Biotechnology from Northwestern University.

Kristen Douglas, Ph.D., Associate Scientist and Group Leader, Late Stage Cell Culture, Genentech, A Member of the Roche Group

Brian Glennon, Ph.D., Associate Professor, Chemical & Bioprocess Engineering, University College Dublin

Brian Glennon is an Associate Professor of Chemical Engineering in the School of Chemical and Bioprocess Engineering in University College Dublin. He is also Chief Scientific Advisor to the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin. in 2011, with Dr Mark Barrett, he founded APC Ltd which provides process engineering technologies and solutions to the international pharmaceutical and biotech industry.

Marc Horner, Ph.D., Lead Technical Services Engineer, ANSYS, Inc.

Dr. Marc Horner is currently working as lead healthcare specialist at ANSYS Inc. Marc joined ANSYS after earning his Ph.D. in Chemical Engineering from Northwestern University in 2001. Marc began by providing support and professional services for biomedical clients, primarily in the areas of cardiovascular devices, drug delivery, packaging, microfluidics and orthopedics. During this time, Marc developed numerous modeling approaches that can be used to establish the efficacy and safety of medical devices. Marc now helps coordinate business and technology development for the health care sector in North America.

Mi Jin, Ph.D., Group Leader, Biologics Process Development, Bristol-Myers Squibb

Mi Jin is a group leader in the Biologics Process Development group at Bristol-Myers Squibb Syracuse, NY site. Her group is responsible for the downstream process development, process characterization, scale up, tech transfer and supporting manufacturing and regulatory filing activities for early to late stage molecules. Prior to joining BMS, Mi Jin did postdoctoral research on protein characterization using mass spectrometry at the Rockefeller University and Cornell University. She holds a Ph.D. in Chemistry and Chemical Biology from Cornell University.

Nikolai Khramtsov, Ph.D., Associate Director, Upstream Development, Protein Sciences Corporation

Nikolai Khramtsov received his Ph.D. in Bioorganic Chemistry from Moscow State University, Russia, and currently he is Associate Director of Upstream Development at Protein Sciences Corporation. He has 17 years of academic and 14 years of industrial experience in discovery, upstream development, process scale up and technology transfer. He has extensive experience in leading the expression proteins in insect, mammalian, yeast, and bacterial systems (batch, fed-batch, chemostat, solid-state fermentation, aerobic and anaerobic).

Michelle LaFond, Associate Director, Bioreactor Scale-Up and Development, Regeneron Pharmaceuticals, Inc.
Michelle joined Regeneron in 1999 as a member of the Bioreactor Scale-Up & Development group within Preclinical Manufacturing and Process Development. She has focused her career on scale-up of CHO-expressed products (recombinant proteins, monoclonal antibodies) to pilot scale for preclinical studies, robustness testing for second generation processes, and is skilled in troubleshooting issues that arise during process scale-up. Michelle has been involved in the development and transfer of processes to Regeneron Manufacturing to produce material for early and late phase human clinical trials and has produced preclinical material for toxicology studies for over 25 programs. Michelle was a lead team member responsible for the specifications and design of Regeneron’s state of the art pilot bioreactor suite constructed in 2009 and in June 2010 was named one of Westchester County’s 40 Under 40 Rising Stars by the Business Council of Westchester. Michelle graduated from University of Connecticut in December 1998 with a Bachelors of Science in Chemical Engineering.

Kishan Rao, M.S., Senior Manager, Technical Services, Alexion Pharmaceuticals

Stefan Schmidt, Ph.D., Vice President, DSP, Rentschler Biotechnology

Dr. Stefan R. Schmidt MBA, currently serves as Vice President at Rentschler Biotechnology, being responsible for the downstream processing department. Previously he held the CSO position at ERA Biotech in Barcelona, directing the company’s R&D efforts focusing on fusion peptides. Prior to that he worked at AstraZeneca in Sweden where he led the unit of Protein Sciences as Associate Director. In the last 10 years he worked intensively with fusion proteins, just recently publishing the first comprehensive book on that topic.

Gerald Striedner, Ph.D., Assistant Professor, Biotechnology, University of Natural Resources and Life Sciences, Vienna

Master in “Food and Biotechnology” and PhD with focus on bioprocess engineering at the Department of Biotechnology at the University of Life Sciences and Natural Resources (BOKU). Current positions, head of the working group microbial fermentation at the Department and project leader in the Austrian Center of Industrial Biotechnology (ACIB). The working group has established an integrated systems approach for bioprocess development and is focused on the implementation of PAT and QbD concepts in bioprocessing. Dr. Striedner is member of the Austrian Assotiation of Molecular Life Sciences and Biotechnology, the European Federation of Biotechnology and the International Society for Pharmaceutical Engineering. Steven Strubbe, DSP Specialist, Merck

Jens Vogel, Ph.D., Executive Director and Head, Process Science, Boehringer Ingelheim

Jens has more than 18 years of experience in biopharmaceutical process development, manufacturing, engineering and global CMC project management. Jens’ current responsibilities include all drug substance and drug product development, clinical supply from disposables and tech transfer for both client and internal projects at BI Biopharma’s US operation. Before joining BI, he was part of Bayer’s Global Biologics Development Leadership Team in Berkeley, California, and also held positions in biotech and pharma in Germany and the UK.

Jörg von Hagen, Ph.D., Director, Global Cell Culture R & D, Merck

Dr. Jörg von Hagen is director of the global Merck Millipore Cell Culture Media Research and Development group. Having studied biotechnology and signal transduction in Giessen and Darmstadt, he received his academic degree with an award-winning thesis in 2001. Dr. von Hagen has more than 10 years of practical expertise in Pharma R&D as scientist in the therapeutic areas cardio vascular and oncology research. After the PDH thesis von Hagen was heading a laboratory for sample preparation in proteomics. Since 2010 von Hagen is responsible for the cell culture media physico chemical research for dry powder cell culture media. He is active member of the European Society of Animal Cell Technology (ESACT) and the Animal Cell Technology Industrial Platform (ACTIP).

Yogesh Waghmare, Ph.D., Process Engineer III, Global Manufacturing Science and Technology, Genzyme a Sanofi Company

Yogesh Waghmare, Ph.D. is currently Team leader for the CFD capabilities at Genzyme. Dr. Waghmare has a decade of experience in the field of fluid dynamics and process modeling. He specializes in application of mathematical modeling tools including computational fluid dynamics (CFD) for process development, scale-up and optimization of bio/pharmaceutical processes. He is past chair of Process Modeling and Simulation Focus Group at American Association of Pharmaceutical Scientists. Dr. Waghmare received his PhD in Chemical Engineering (2008) from Louisiana State University researching in the field of mass transfer and multiphase flows. He has published several research articles and presented at number of conferences in his area of expertise.

LiYing Yang, Ph.D., Scientist II, Manufacturing Sciences & Technology, MedImmune, Inc.

Dr. Yang received her Ph.D. from the Ohio State University at the Biochemical and Molecular Biology Department. Then she joined Bristol-Myers Squibb in the Department of Manufacturing sciences. She worked on process characterization using bioreactor scale-down models, and technology transfer and scaling-up of mammalian cell culture processes. She then joined MedImmune in their large scale mammalian cell culture facility in Frederick, MD, in the department of manufacturing Sciences & Technology. With years of experience in bioreactor scale-up and scale-down model development and qualification, Dr. Yang has experience in both commercial scale and bench-scale bioreactor operations.

Speaker Bios
Optimizing Cell Line Development
August 21-22, 2014

 

Howard Clarke, Ph.D., Director, Upstream Process Development, CMC Biologics 

Dr. Clarke is Director of Upstream Process Development at CMC ICOS, a GMP contract manufacturing organization, and has over twenty years of cell and molecular biology experience in both industrial and academic institutions. He received his Ph.D. in 1994 from the University of Washington studying gene regulation in plants and then spent nine years (1994-2003) at Immunex/Amgen Corporation developing and improving protein expression technology in yeast and mammalian cells. Dr. Clarke returned to the University of Washington to build and direct a core molecular biology facility at the Center for Cell Dynamics studying the role of structural proteins in developing embryos. He joined CMC ICOS in 2008 and currently oversees the molecular expression, cell line development, and cell culture process development groups, integrating new technology developments to optimize existing expression platforms in CHO cells.

Wian de Jongh, Ph.D., CSO, ExpreS2ion Biotechnologies

Dr. de Jongh (South African) obtained a Bachelor degree followed by a M.Sc. in Chemical Engineering from the University of Stellenbosch, South Africa. Thereafter, he was awarded a doctorate in Biotechnology from the Danish technical University (DTU) in 2006. During his PhD, Dr. de Jongh developed advanced cell line genetic engineering tools and applied metabolic engineering methodologies to cell lines with engineered improved production characteristics. Dr. de Jongh has significant experience in the pharmaceutical industry in cell line development; project management; upstream process development; and process transfer to cGMP manufacturing. Furthermore, Dr. de Jongh was instrumental in the development of the proprietary expression vector system ExpreS2ion Biotechnologies was founded on.

Scott Estes, Ph.D., Director, Cell Culture Development, Biogen Idec

John Follit, Ph.D., Scientist I, Cell Line Technology, Biogen Idec, Inc.

John earned his Ph.D. in Biomedical Sciences from the University of Massachusetts in 2012 where he focused on intracellular protein trafficking. Upon graduation, John joined BiogenIdec as a member of the Cell Line Technology team. At Biogen, John’s work focuses on host cell engineering and platform innovation aimed at improving host cell productivity.

Ian Fotheringham, Ph.D., President & Co-Founder, Industrial Biotechnology, Ingenza, Ltd.

Dr. Ian Fotheringham is the President and co-founder of Ingenza, Ltd. Ian has over 25 years experience in biocatalysis, bio-engineering and industrial bioprocess development. Previously Ian developed the microbial strains used in the manufacturing of L-phenylalanine for the aspartame sweetener as well as almost a dozen other commercial pharmaceutical intermediates. He is an inventor on nine issued patents.

Molly Jenkins, Ph.D., Research Fellow, Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College

Molly Jenkins, PhD, is a Postdoctoral Research Fellow at the Geisel School of Medicine at Dartmouth College in Lebanon, NH. Her predoctoral training in cancer cell biology, matrix metalloproteinases (MMPs), and extracellular matrix proteins has provided a foundation for her current research, which focuses on investigating the molecular and cellular mechanisms that mediate melanoma metastasis. As part of her predoctoral training in Dr. Kyuson Yun’s laboratory, Dr. Jenkins’ research involved the identification and isolation of cancer stem cells from mouse brain tumors. As a PhD candidate with Dr. Clarissa Henry, she expanded her research interests to investigating the role of MMPs in cancer progression, particularly how MMPs remodel the extracellular matrix during cancer metastasis as well as during normal development. As a Postdoctoral Fellow at Dartmouth with Drs. Constance Brinckerhoff and David Mullins, Dr. Jenkins has continued to develop her interests in cancer biology and has recently developed cell lines from a conditional mouse model of metastatic BRafV600E melanoma (Pigment Cell and Melanoma Research, 2014). These cell lines uniquely allow researchers to correlate in vitro studies on molecular mechanisms of melanoma with in vivo investigations on pathology and immunology in syngeneic hosts. Dr. Jenkins plans to use these cell lines for her future work investigating molecular mechanisms mediating melanoma metastasis, which will be the basis for developing novel therapeutic strategies to block tumor progression.

Sohye Kang, Ph.D., Senior Scientist, Product Attribute Sciences, Amgen, Inc.

I am a Senior Scientist at Amgen, in the department of Product Attribute Sciences (PAS). My current research focus is identifying genetic and metabolic markers and pathways associated with productivity and product quality by applying various systems biology tools, including proteomics, metabolomics, transcriptomics and lipidomics, and formulating functional application strategies to advance cell line engineering and process optimization. Prior to joining PAS, I was involved in the cell line development and media optimization efforts in Cell Science and Technology department at Amgen. Prior to Amgen, I was a postdoctoral fellow at The Scripps Research Institute (La Jolla, CA), investigating various oncogenic signaling pathways. I received a Ph.D. in Cell and Molecular Biology from University of California, San Diego and San Diego State University.

Gregory Keil, M.S., Senior Scientist, Merck

Gregory Keil graduated from Stockton College of New Jersey with a BS in Biochemisry and Molecular Biology. He then went on to attend graduate school at the Pennsylvania State University where he received an MS in Biochemistry and Molecular Biology. After graduate school, Gregory took a position at Merck in Bioprocess Technology and Expression where his main focus is on high-throughput automation within bioprocess development.

Frank Kensy, Ph.D., Managing Director, m2p-labs, Inc.

Dr.-Ing. Frank Kensy studied Biochemical Engineering at the University Essen, Madrid and at RWTH Aachen. After receiving his diploma, he first started his professional career as fermentation scientist for new recombinant enzymes and pharmaceutical proteins at Rhein Biotech N.V. in Düsseldorf. In 2002 he decided to return to RWTH Aachen University for doing his PhD on shaken microbioreactors with Prof. Jochen Büchs. Since November 2005 he is founder and managing director of m2p-labs responsible for R&D and sales.

Amanda Lanza, Ph.D., Scientist, Bristol-Myers Squibb Co.

Amanda earned her B.S. from the Massachusetts Institute of Technology and her PhD from The University of Texas at Austin, both in chemical engineering. As a graduate student, she was the fortunate recipient of many fellowships, including a National Science Foundation graduate research fellowship and the prestigious Harrington Dissertation fellowship. Her graduate work focused on developing advanced genetic tools for eukaryotic cell line engineering. In 2013, she joined Bristol-Myers Squibb’s Biologics Development group in their Massachusetts office. At BMS, her primary focus is process development for both mid and late stage molecules. Additionally, she is interested in using ‘omics technologies to drive advancements in Bioprocess development.

Jehyuk Lee, M.D., Ph.D., Genetics, Wyss Institute for Biologically Inspired Engineering, Harvard University

Jay Lee received B.S. from the University of Pennsylvania (1992) and M.D. Ph.D. from Tufts School of Medicine (2002) while studying transcriptional regulation in MAP kinase-induced tumor suppression. He entered internal medicine residency at the Hospital of University of Pennsylvania and briefly worked at Abington Memorial Hospital before joining the laboratory of George Church at Harvard Medical School as a research fellow (2006). He was actively involved in generation of openly consented human cell lines from Personal Genome Project, including induced pluripotent stem cells. He also helped to characterize various human cell types using next generation sequencing technologies, including full genome sequencing, methylation profiling and allele-specific gene expression. His main focus is developing high-throughput technologies for characterizing single cells and tissues in a massively parallel manner in situ. He has worked at Wyss Institute for Bioinspired Engineering as a research scientist since 2013. His interests include population-based cell assays in Organs-on-Chip for drug screening, next generation in situ tumor diagnostic tools, tissue engineering for controlled drug delivery and technology development and transfer.

Pierre Moretti, Ph.D., Staff Scientist and Head, Cell Line Development, Glenmark Pharmaceuticals
Pierre graduated from the Leibniz University Hanover in Germany and completed his PhD thesis with focus on stem cell and cytokine research in the research group of Prof. Thomas Scheper in Hanover. He joined Glenmark’s research center in Switzerland in 2010 and developed ever since cell line platforms for the expression of NBE such as monoclonal antibodies and new bispecific formats. Pierre is currently Head of Cell Line Development and scientific adviser for early Upstream Process Development.

Andrew Sandford, Vice President, Global Business Development, Biologics, Catalent Pharma Solutions

Andrew Sandford serves as Vice President of Global Business Development, Biologicsfor Catalent Pharma Solutions, the leading global provider of development solutions and advanced delivery technologies for drugs, biologics, and consumer health products. Mr. Sandford leads Catalent’s planning and market intelligence efforts, as well as supporting global network in the Pharmaceutical and Biotechnology market with domain knowledge of biologics manufacturing methodologies and technologies, preclinical and clinical operational structures. A microbiologist by education, Andrew Sandford has been building businesses around innovative offerings for over 20 years. Prior to joining Catalent, Andrew served as Vice President of Business Development for Selexis, Inc., a subsidiary for Selexis SA, where he established the U.S. subsidiary of the company and was responsible for global transactional and strategic value creation. Prior to this, Andrew worked in Dow Chemical’s Ventures unit where he established and launched the highly successful Pfenex business unit. Subsequent to Dow Ventures, Andrew worked for Cambrex Biopharma, which was latterly acquired by Lonza Biologics. He holds several professional leadership certifications, and is a graduate of the State University of New York College of Plattsburgh.

Armon Sharei, Ph.D., Research Associate, Chemical Engineering, Massachusetts Institute of Technology (MIT), and Co-Founder, SQZ Biotech

Dr. Armon Sharei received his Ph.D. in Chemical Engineering from MIT under the guidance of Prof. Klavs Jensen and Prof. Robert Langer. He was a national finalist for the NIH Director’s Early Independence Award in 2013 and is co-founder and chairman of SQZ Biotechnologies. His team has focused on developing microfluidic methods for robust intracellular delivery of materials for research and clinical applications. Their work has shown much potential in fields ranging from stem cell engineering to immunotherapies. Dr. Sharei is a co-author on 9 peer-reviewed publications and is an inventor on 3 patents.

David Shaw, Ph.D., Group Leader, Early Stage Cell Culture, Pharma and Technical Development, Genentech, Inc.

David joined Genentech in 2010 and is currently a Scientist and Group Leader in the Early Stage Cell Culture department.  Prior to Genentech, he was the Head of Molecular Biology and Protein Sciences at Roche Palo Alto. David has a Ph.D. from the University of South Carolina and was a Research Professor at the South Carolina Cancer Center.

Till Wenger, Ph.D., Associate Director, Cell Biology & Cell Culture II, Process Sciences, Boehringer Ingelheim Pharma

Biochemist by training, active in the field of cell biology for 15 years. PhD thesis on tumor cell biology, tumor cell apoptosis and cell death resistance mechanisms at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Postdoc in cell biology and immunology at the Centre d’Immunologie de Marseille-Luminy (CIML) in Marseille, France, focusing on the cell biology of dendritic cells, regulation of antigen presentation, autophagy and translation regulation. Joined Boehringer Ingelheim, Biberach, Germany, in 2011. Leading the Cell Biology I lab, responsible for development of biopharmaceutical production cell lines, and technology development projects focusing on production cell lines and cell line development approaches.

Yuansheng Yang, Ph.D., Research Scientist, Animal Cell Technology, Bioprocessing Technology Institute

Dr. Yuansheng Yang received his doctorate degree from Vanderbilt University’s Department of Chemical Engineering in 2005. Upon graduation, he joined the Animal Cell Technology group, Bioprocessing Technology Institute (BTI) in Singapore as a research scientist. He became an adjunct assistant professor of Nanyang Technological University in 2012. He is currently leading a group working on vector design, cell line development, cell engineering, and bioprocess optimization to enhance the yield and quality of biopharmaceutical drugs produced using CHO cells. He has published over 20 papers and filed several patents related to developing cell lines for high level expression of monoclonal antibodies and other recombinant proteins.

Bo Yu, Ph.D., Co-Founder and Chief Scientific Officer, Larix Bioscience, LLC

Dr. Yu is the inventor of Antibody Membrane Switch (AMS) technology. Following completion (1999) of a Ph.D. in Biochemistry from the California Institute of Technology (Caltech) and postdoctoral training at Stanford University, his career in biotechnology has focused on antibody engineering, humanization, and development of antibody therapeutics. He was a member of the founding scientific team and a senior scientist at Kalobios Pharmaceuticals (2001-2007). Subsequently, he was a general manager at Shanghai KH Weichi biotechnologies (2007-2010) and a senior scientist at Aragen Bioscience (2011-2012).

Jesús Zurdo, Ph.D., Head, Innovation, Biopharma Development, Lonza Biologics plc

Jesús Zurdo is Head of Innovation, Biopharma Development at Lonza. He has an extensive trajectory in bioprocessing innovation and biopharmaceutical development de-risking and was one of the early introducers of developability methodologies to biological drugs. Jesús cofounded Zyentia to develop solutions for protein aggregation and disease-modifying therapies for Parkinson’s, Alzheimer’s and type 2 diabetes. While at Zyentia, he held various roles, including CSO and CEO, until the acquisition of the AggreSolve platform by Lonza in 2007. He was also cofounder and Scientific Advisor of Zapaloid, overseeing drug discovery programmes in neurodegeneration. Jesús held several research positions at the Universities of Oxford and Cambridge in the UK and prior to that at CBM-CSIC in Spain. He has a PhD in molecular biology from the Autonomous University of Madrid.